Budesonide chemical structure
Find information on thousands of medical conditions and prescription drugs.

Budesonide

Budesonide is a corticosteroid for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. Additionally, it is used for inflammatory bowel disease. It is marketed by AstraZeneca as a nasal inhalation with the brand name Rhinocort, as an oral inhalation with the brand name Pulmicort, and as an enema and a modified-release capsule with the brand name Entocort. It is also sold in combined with formoterol (Oxis) in a single inhaler, with the brand name Symbicort. more...

Home
Diseases
Medicines
A
B
Baciim
Bacitracin
Baclofen
Bactrim
Bactroban
Barbexaclone
Barbital
Baros
Basiliximab
Baycol
Beclamide
Beclometasone
Beclovent
Beconase
Beldin
Benadryl
Benazepril
Bendroflumethiazide
Benserazide
Bentiromide
Benylin
Benzaclin
Benzalkonium chloride
Benzocaine
Benzonatate
Betacarotene
Betadine
Betahistine
Betamethasone
Betaxolol
Bextra
Biaxin
Bibrocathol
Bicalutamide
Bicillin
Biclotymol
Biotin
Bisoprolol
Bleomycin
Blocadren
Boldenone
Boniva
Bontril
Bosentan
Bravelle
Brethaire
Brevibloc
Brevicon
Bricanyl
Bromazepam
Bromelain
Bromhexine
Bromocriptine
Brompheniramine
Bronkodyl
Bronopol
BSS
Bucet
Budesonide
Bumetanide
Bupivacaine
Buprenex
Buprenorphine
Buserelin
Buspar
Buspirone
Busulfan
Butalbital
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Budesonide has a high first pass metabolism. It has efficacy in the terminal ileum and the right colon. It has a lower incidence of systemic manifestations than similar medications.

Read more at Wikipedia.org


[List your site here Free!]


Effects of budesonide on overall 5-methylcytosine levels and specific methylation and messenger RNA expression of the insulin-like growth factor II gene
From CHEST, 5/1/04 by Ronald Lubet

Abbreviations: IGF = insulin-like growth factor; SMC = 5-methylcytosine

The effects of limited treatment with budesonide, an effective chemopreventive agent, on 5-methylcytosine (SMC) levels, and on the specific hypomethylation and expression of the insulin-like growth factor (IGF) II gene in mouse lung tumors was determined. Female strain A mice were administered two weekly doses of vinylcarbamate intraperitoneally. Thirty-four weeks later, mice were administered dietary budesonide (2.4 or 0.6 ppm in diet) or vehicle control for a period of 7 days and then were killed. We found that the level of 5MC in lung tumor's, measured immunologically, was reduced roughly 60% when compared with normal lung parenchyma, which is in agreement with generalized hypomethylation in many tumors. In contrast, tumors treated with budesonide for 7 days exhibited a dose-dependent increase in 5MC, with the higher dose giving 5MC levels similar to control lung parenchyma.

We subsequently examined gene expression and methylation patterns for the IGF II gene in both control tumors and tumors treated for 1 week with budesonide. Expression levels of the IGF II gene were increased roughly 2.5-fold in tumors vs normal lung parenchyma. This overexpression was reversed by treatment with budesonide for a period of 7 days. We also examined the methylation at CpG sites within the DMR2 region, which includes exons 4, 5, and 6. Within the examined region of roughly 600 nucleotides, there were 27 CpG sites. The determination of methylation in this region employed DNA isolation and bisulfite treatment, followed by amplification, cloning, and subsequent sequencing. The percentage of methylated CpG sites was 70% for normal lung parenchyma, 5% for control lung tumors, and 16% and 46% for lung tumors treated with budesonide (0.6 or 2.4 ppm, respectively, in diet) for 1 week. Thus, a chemopreventive agent, budesonide, could rapidly reverse both the generalized and specific hypomethylation observed in mouse lung tumors.

* From the Chemopreventive Agent Development Research Group-Division of Cancer Prevention (Dr. Lubet), National Cancer Institute, Rockville, MD; and the Department of Pathology (Drs. Tao, Wang, Kramer, and Perreira), Medical College of Ohio, Toledo, OH.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: permissions@chestnet.org).

Correspondence to: Ronald A. Lubet, PhD, Program Director, NCI-DCP, Rm 2110, 6130 Executive Dr. Rockville, MD 20852; e-mail: rl57q@nih.gov

COPYRIGHT 2004 American College of Chest Physicians
COPYRIGHT 2004 Gale Group

Return to Budesonide
Home Contact Resources Exchange Links ebay